Core Viewpoint - The company, Gilead Sciences-B (01672.HK), has announced a voluntary commitment by its founder and major shareholders to not sell any shares before the release of three key clinical trial data points, reflecting their confidence in the company's long-term value and future prospects [1] Group 1: Shareholder Commitment - Dr. Wu Jinzi and Ms. He Jingdao have committed to not selling or pledging any shares they control until the release of three specific clinical trial results [1] - The three clinical data readouts include: (i) top-line data from the U.S. Phase I clinical study of ASC47 combined with semaglutide in obese subjects, expected by the end of September 2025; (ii) top-line data from the U.S. 13-week Phase IIa clinical study of ASC30 oral tablets in obese or overweight subjects, expected by the end of December 2025; and (iii) top-line data from the U.S. Phase I single ascending dose study of ASC50 in healthy subjects, also expected by the end of December 2025 [1] - As of the announcement date, the total number of voluntarily locked-up shares held by Dr. Wu and Ms. He is approximately 576 million shares, representing about 58.03% of the company's existing issued share capital (excluding treasury shares) [1]
歌礼制药-B(01672.HK)控股股东作出自愿禁售承诺 押注三大临床研究结果